Around 40% of people diagnosed with multiple myeloma survive 10 years or more, based on population data from England and Wales tracked through 2019. That number has improved dramatically over the past few decades and continues to climb as newer treatments become available. But individual outcomes vary widely depending on age, the genetic profile of the cancer, and how well it responds to initial treatment.
How Survival Has Changed Over Time
Multiple myeloma was once considered a rapidly fatal disease. Median survival (the point at which half of patients are still alive) was just 1.7 years for people diagnosed between 1970 and 1984. That rose to 3 years for those diagnosed between 1985 and 1999, when high-dose chemotherapy followed by stem cell transplant became standard. For patients diagnosed from 2000 onward, median survival jumped to 5.1 years, driven largely by a new generation of drugs that attack myeloma cells through different mechanisms.
That 40% ten-year figure reflects a mix of patients diagnosed across several eras. People being diagnosed today, with access to the latest treatment combinations, are likely to do better than the historical average suggests. The gap between older statistics and current reality is one of the most important things to understand about myeloma prognosis.
What Stage Means for Survival
Doctors use a system called R-ISS (Revised International Staging System) to classify myeloma into three stages based on blood test results and genetic markers. Five-year survival rates by stage give a clearer picture of how outcomes differ:
- R-ISS Stage I: 82% five-year survival. These patients have lower tumor burden and no high-risk genetic changes.
- R-ISS Stage II: 62% five-year survival. An intermediate category.
- R-ISS Stage III: 40% five-year survival. These patients have higher levels of a protein called LDH, more advanced disease markers, or high-risk chromosomal abnormalities.
Ten-year data broken down by stage is harder to find because the R-ISS system is relatively new. But the stage at diagnosis remains one of the strongest predictors of long-term outcome.
Age Makes a Significant Difference
Younger patients consistently do better. For people diagnosed at age 50 or younger, the five-year relative survival rate is 82% and the ten-year rate is 58%. That’s notably higher than the overall population average, partly because younger patients are more likely to tolerate aggressive treatment and qualify for stem cell transplant.
Most myeloma patients are diagnosed in their late 60s or 70s, when other health conditions can limit treatment options and affect survival independently. Age alone doesn’t determine outcome, but it shapes which treatments are feasible.
How Genetics Influence Prognosis
Not all myeloma behaves the same way at the cellular level. Certain chromosomal abnormalities found through a test called FISH make the disease harder to control. The most well-known high-risk markers include deletions or rearrangements on specific chromosomes (known in clinical shorthand as del(17p), t(4;14), t(14;16), t(14;20), and gain(1q21)).
In real-world data, patients with these high-risk genetic features had roughly double the risk of their disease progressing and of dying compared to standard-risk patients. A hazard ratio of 2.28 for death means the risk of dying at any given time point is more than twice as high. These patients still benefit from treatment, but they tend to relapse sooner and may need more lines of therapy over time.
Stem Cell Transplant and Long-Term Survival
Autologous stem cell transplant, where your own stem cells are collected and returned after high-dose chemotherapy, remains a cornerstone of treatment for eligible patients. In a study of over 1,400 transplant recipients, 28% qualified as long-term survivors. The remaining 72% had shorter survival, though “short-term” in this context still often means several years.
Transplant doesn’t cure myeloma in most cases. It deepens the initial response and extends the time before the disease returns. For patients who respond well, transplant can add years of remission, and some patients remain in remission for a decade or longer.
Why Depth of Response Matters
One of the most meaningful predictors of long-term survival is how completely treatment eliminates detectable myeloma cells. Doctors can now measure this with extraordinary sensitivity using a test for minimal residual disease (MRD). When no myeloma cells can be detected even at a level of one in a million, a patient is considered MRD-negative.
Reaching MRD-negative status is good. Staying there is even better. Patients who maintain MRD negativity over time (called “sustained” MRD negativity) have the best outcomes. In one study, patients who achieved MRD negativity after two years of maintenance therapy had only a 17.2% chance of progressing over the following four years. By contrast, patients who initially tested MRD-negative but later became positive again actually fared worse than some patients who never cleared their disease completely.
This finding is reshaping how doctors think about treatment duration. Some patients who maintain deep remission may eventually be able to pause treatment, entering what’s called treatment-free surveillance. In early studies, patients with sustained MRD negativity who entered surveillance had a two-year progression-free survival rate of 87%.
Newer Treatments Are Extending Survival Further
For patients whose myeloma returns after multiple prior treatments, a new class of therapy called CAR-T cell therapy is showing promise. In this approach, a patient’s own immune cells are engineered to recognize and attack myeloma. Early long-term data from one CAR-T product showed a median overall survival of 50.2 months (just over four years) in patients who had already exhausted other options. Median progression-free survival was about 22.6 months.
These numbers are especially notable because they come from patients with heavily pretreated, relapsed disease, the hardest population to help. CAR-T and a related class called bispecific antibodies are now being studied earlier in the treatment course, where their impact on long-term survival could be even greater.
Health Risks for Long-Term Survivors
People who survive myeloma for 10 years or more face some ongoing health concerns beyond the myeloma itself. Survivors have an elevated risk of developing a second, unrelated cancer, particularly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Both are blood cancers that can arise partly as a consequence of prior chemotherapy or radiation exposure.
Bone damage from myeloma can also persist long after treatment, and kidney function may remain impaired in patients who had significant kidney involvement at diagnosis. Regular monitoring after treatment helps catch these complications early, when they’re most manageable.